CDER’s Automated NDA Assessment Tool May Expand Beyond Clinical Reviews
Executive Summary
“JumpStart” analytics service provides data fitness assessments and exploratory safety analyses to clinical reviewers within two weeks following NDA/BLA submission.
You may also be interested in...
FDA “JumpStart” Data Service Gives Reviewers Leg Up On Complex NDAs
A new time-saving review tool at FDA, JumpStart, “partitions” the work on an NDA or BLA by asking data experts in the Office of Computational Science to run initial analyses and flag areas for follow-up by the review teams.
FDA “JumpStart” Data Service Gives Reviewers Leg Up On Complex NDAs
FDA is looking for ways to make the review process more efficient, especially as biopharma applications become more data-heavy and complex. One new time-saving review tool at FDA, JumpStart, “partitions” the work on an NDA or BLA by asking data experts in the Office of Computational Science to run initial analyses and flag areas for follow up by the review teams. It’s been a big hit in the Office of New Drugs.
PDUFA Negotiations Focus On Review Delays; Firms, FDA See Different Causes
Industry appears to be showing its strongest hand as PDUFA V negotiations roll along, laying down the cards showing FDA's poor record of meeting user fee goals in recent years